Serum Interleukin-36 in Pityriasis Rosea: A Potential Biomarker for Disease Severity.

Eman M Sanad, Mays Ibrahim, Maha Rachwan, Ghada M Shams

Open access · greenAbstract read

In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.5field-weighted citation impact, top 31% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

Herald Patch as the Only Evidence of Pityriasis Rosea: Clinical, Laboratory and Pathogenetic Features.Viruses · 2025
Observational
Comparative Efficacy of Different Pharmacological Treatments for Pityriasis Rosea: A Network Meta-Analysis.Journal of clinical medicine · 2024
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eman M SanadDr. Sanad and Dr. Shams are with the Department of Dermatology, Venereology and Andrology, and Faculty of Medicine at Benha University, in Banha, Egypt.

Mays IbrahimMr. Ibrahim is with the Faculty of Medicine at Benha University in Banha, Egypt.

Maha RachwanDr. Rachwan is with the Department of Clinical and Chemical Pathology, Faculty of Medicine at Benha University in Banha, Egypt.

Ghada M ShamsDr. Sanad and Dr. Shams are with the Department of Dermatology, Venereology and Andrology, and Faculty of Medicine at Benha University, in Banha, Egypt.

Benha University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Pityriasis rosea (PR) is a self-limiting acute rash with unclear etiology and pathogenesis. The cytokine profile of PR is an infrequently investigated field of research. The aim of this study was to assess the level of IL-36 in sera of patients with PR and its possible interrelation with disease severity. Methods: Forty patients with PR were included in this case-control study, and 40 comparable healthy control subjects. Severity was assessed using pityriasis rosea severity score (PRSS) and serum IL-36 was assessed using ELISA. Results: Serum IL-36 was significantly higher in patients (30.36±12.35) pg/mL compared to control subjects (18.76±10.24) pg/mL (P=0.003). It correlates positively with severity as assessed by PRSS ( Conclusion: Serum IL-36 could be considered a potential biomarker for pityriasis rosea that correlates with the disease severity.

Indexed as

COVID-19Interleukin-36Pityriasis rosea

Identifiers

PMID37288282

PMCPMC10243729

OpenAlexW4379769486

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.